应对美国阿片类物质流行病的医院策略的临床影响、成本与成本效果:一项建模研究
该建模研究比较四种医院策略应对美国阿片类物质流行病。与标准诊疗相比,扩展阿片类物质使用障碍药物处方并联合成瘾咨询服务的策略可降低住院和过量死亡,在每获得1个生命年支付10万美元的意愿支付阈值下具有成本效果。
要点
- 扩展阿片类物质使用障碍药物处方并联合成瘾咨询服务可降低住院和过量死亡。
- 在每获得1个生命年支付10万美元的意愿支付阈值下,两种扩展策略均具有成本效果。
- 理想减害服务可及性情景的结论与基础病例一致,结果在敏感性分析中稳健。
核心结论
- 扩展医院内阿片类物质使用障碍药物处方并实施成瘾咨询服务的联合干预可提高预期寿命、具有成本效果,并可作为美国及类似阿片类物质流行病国家综合医院策略的基础。
研究设计与样本
- 研究采用微观模拟模型,比较标准医院诊疗(阿片类物质脱毒、无成瘾咨询服务,即现状)、扩展住院阿片类物质使用障碍药物处方(包括桥接处方)、实施医院内成瘾咨询服务、以及阿片类物质使用障碍药物联合成瘾咨询服务的联合策略。
- 模型输入来自临床试验和观察性队列。
- 结局包括生命年、贴现成本、增量成本效果比、住院和死亡。
- 进行了关键模型输入(药物使用成本和后遗症相关)的确定性敏感性分析和概率敏感性分析。
主要发现
- 在美国注射阿片类物质人群中,与现状相比,扩展阿片类物质使用障碍药物处方并包括桥接处方可分别降低住院和过量死亡3.2%和3.6%。
- 与现状相比,扩展阿片类物质使用障碍药物处方联合成瘾咨询服务可分别降低住院和过量死亡5.2%和6.6%。
- 每人平均终生成本从731 400美元(95%可信区间447 911-859 189,阿片类物质使用障碍药物策略)到741 200美元(470 930-868 551,联合策略)。
- 假设每获得1个生命年支付10万美元的意愿支付阈值,阿片类物质使用障碍药物联合桥接处方策略和联合策略具有成本效果(分别为7 600美元和14 300美元)。
- 假设理想减害服务可及性的情景得出与基础病例相同的结论,结果在确定性和概率敏感性分析中稳健。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The syndemic of injection drug use and serious injection-related infections is leading to increasing mortality in the USA. Although outpatient treatment with medications for opioid use disorder reduces overdose risk and recurrent infections, hospitalisation remains common. We evaluated the clinical impact, costs, and cost-effectiveness of hospital-based strategies to address the US opioid epidemic. METHODS: We developed a microsimulation model to compare the cost-effectiveness of: standard hospital care-detoxification for opioids, no addiction consult service (status quo); expanded inpatient prescribing of medications for opioid use disorder, including bridge prescriptions (ie, medication until they can see an outpatient provider) when possible (medications for opioid use disorder with bridge); implementation of addiction consult services within the hospital (addiction consult services alone); and a combined medication for opioid use disorder with addiction consult services strategy (combined). We used clinical trials and observational cohorts to inform model inputs. Outcomes were life-years, discounted costs, incremental cost-effectiveness ratios, hospitalisations, and deaths. We did deterministic sensitivity analyses on key model inputs related to costs and sequelae of drug use and probabilistic sensitivity analysis to further address uncertainty. FINDINGS: Among people who inject opioids in the USA, we estimated that expanding medications for opioid use disorder with bridge prescriptions would reduce hospitalisations and overdose deaths by 3·2% and 3·6%, respectively, and the combination of expanded medications with opioid use disorder along with addiction consult sevices would reduce hospitalisations and overdoses by 5·2% and 6·6%, respectively, compared with the status quo. Mean lifetime costs ranged from US$731 400 (95% credible interval 447 911-859 189 for the medications for opioid use disorder strategy) to $741 200 (470 930-868 551 for the combined strategy) per person. Assuming a willingness-to-pay threshold of $100 000 per life-year gained, medications for opioid use disorder with bridge and combined strategies were cost-effective ($7600 and $14 300, respectively). A scenario that assumed ideal access to harm reduction services came to the same conclusions as the base case and our results were robust in deterministic and probabilistic sensitivity analyses. INTERPRETATION: The combined interventions of expanding hospital-based prescribing of medications for opioid use disorder and implementing addiction consult services could improve life expectancy, be cost-effective, and could be the basis for a comprehensive hospital-based strategy for addressing the opioid epidemic in the USA and countries with similar opioid epidemics. FUNDING: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.
引用
- Barocas JA, Savinkina A, Adams J, et al. Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. Lancet Public Health. 2021. PMID: 34861189. doi:10.1016/S2468-2667(21)00248-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。